EB66 cell line, a duck embryonic stem cell-derived substrate for the industrial production of therapeutic monoclonal antibodies with enhanced ADCC activity

Abstract

(2010) EB66 cell line, a duck embryonic stem cell-derived substrate for the industrial production of therapeutic monoclonal antibodies with enhanced ADCC activity, mAbs, 2:4, 405-415,

Marketing approval of mogamulizumab

“…Antibodies produced in EB66 cells display a naturally reduced fucose content resulting in enhanced ADCC activity 23 . A comparative N-linked oligosaccharide analysis of CHO- and EB66-produced rituximab was performed by mass spectrometry, as well as in vitro ADCC assays.…”

2.3 Cell Lines for Vaccine Production

“…Many topics have not been reviewed here, including details on health regulatory requirements; technical aspects of improved bioreactor technologies and novel purification options; certain cell lines such as the diploid FRhL-2 cell line derived from the lung of a fetal rhesus monkey and used in the production of the (now withdrawn) RotaShield vaccine; cell lines used for the production of some veterinary viral vaccines, including vaccines to protect companion animals or animals intended for human consumption; and the fascinating field of stem cell lines, where at least one (EB66) [143] is on the regulatory track for approval of vaccine production.…”

1st French-Israeli International Conference on B Cells and therapeutic antibodies

“…This technology has been successfully applied by Vivalis for generatation of high affinity mAbs against an infectious target. Finally, Dr. Mehtali described the use of the EB66® cell line, derived from duck embryonic stem cells, to produce low-fucosylated mAbs with enhanced antibody-dependent cell-mediated cytotoxicity (ADCC) 9 . These cells can proliferate in suspension in stirred-tank bioreactors to reach high cell densities in serum-free media, with a yield of mAb production of about 1 g/L.…”